Diaceutics (DXRX) Share Price, News & Analysis

Company Overview

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Key Stats

• Today's Range: 120 to 122.50
• 50-Day Range: 120 to 147
• 52-Week Range: 95 to 151
• Volume: 42,096 shs
• Average Volume: 112,925 shs
• Market Capitalization: £101.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: GBX 160
• Consensus Rating: Buy

DXRX Stock Analysis - Frequently Asked Questions

How have DXRX shares performed this year?

Diaceutics' stock was trading at GBX 123 at the start of the year. Since then, DXRX stock has decreased by 2.4% and is now trading at GBX 120.
View the best growth stocks for 2025 here.

How do I buy shares of Diaceutics?

Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Diaceutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Diaceutics investors own include 4D pharma (DDDD), Rolls-Royce Holdings plc (RR.L), Abcam (ABC), B&M European Value Retail (BME), BP (BP), Coats Group (COA) and genedrive (GDR).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: LON:DXRX
• CIK: N/A
• Web: www.diaceutics.com
• Phone: N/A
• Fax: N/A
• Employees: 151
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 160
• High Stock Price Target: GBX 160
• Low Stock Price Target: GBX 160
• Potential Upside/Downside: +33.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX (3.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 118.72
• P/E Growth: N/A
• Net Income: £-2,843,065.67
• Net Margins: -10.90%
• Pretax Margin: N/A
• Return on Equity: -7.15%
• Return on Assets: -6.06%

Debt

• Debt-to-Equity Ratio: 0.39
• Current Ratio: 4.85
• Quick Ratio: 9.92

Sales & Book Value

• Annual Sales: £26.08 million
• Price / Sales: 3.88
• Cash Flow: GBX 38.46 per share
• Price / Cash Flow: 3.12
• Book Value: GBX 45.87 per share
• Price / Book: 2.62

Miscellaneous

• Outstanding Shares: 84,393,829
• Free Float: N/A
• Market Cap: £101.27 million
• Optionable: Not Optionable
• Beta: 0.58